Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mechanisms of Targeting the MDM2-p53-FOXM1 Axis in Well-Differentiated Intestinal Neuroendocrine Tumors.
Briest F, Grass I, Sedding D, Möbs M, Christen F, Benecke J, Fuchs K, Mende S, Kaemmerer D, Sänger J, Kunze A, Geisler C, Freitag H, Lewens F, Worpenberg L, Iwaszkiewicz S, Siegmund B, Walther W, Hummel M, Grabowski P. Briest F, et al. Among authors: freitag h. Neuroendocrinology. 2018;107(1):1-23. doi: 10.1159/000481506. Epub 2017 Sep 14. Neuroendocrinology. 2018. PMID: 28910819
Long-term symptom severity and clinical biomarkers in post-COVID-19/chronic fatigue syndrome: results from a prospective observational cohort.
Legler F, Meyer-Arndt L, Mödl L, Kedor C, Freitag H, Stein E, Hoppmann U, Rust R, Wittke K, Siebert N, Behrens J, Thiel A, Konietschke F, Paul F, Scheibenbogen C, Bellmann-Strobl J. Legler F, et al. Among authors: freitag h. EClinicalMedicine. 2023 Aug 19;63:102146. doi: 10.1016/j.eclinm.2023.102146. eCollection 2023 Sep. EClinicalMedicine. 2023. PMID: 37662515 Free PMC article.
FOXM1: A novel drug target in gastroenteropancreatic neuroendocrine tumors.
Briest F, Berg E, Grass I, Freitag H, Kaemmerer D, Lewens F, Christen F, Arsenic R, Altendorf-Hofmann A, Kunze A, Sänger J, Knösel T, Siegmund B, Hummel M, Grabowski P. Briest F, et al. Among authors: freitag h. Oncotarget. 2015 Apr 10;6(10):8185-99. doi: 10.18632/oncotarget.3600. Oncotarget. 2015. PMID: 25797272 Free PMC article.
The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S, Rentsch J, Freitag H, Detjen K, Briest F, Möbs M, Weissmann V, Siegmund B, Auernhammer CJ, Aristizabal Prada ET, Lauseker M, Grossman A, Exner S, Fischer C, Grötzinger C, Schrader J, Grabowski P; GERMAN NET-Z study group. Nölting S, et al. Among authors: freitag h. PLoS One. 2017 Aug 11;12(8):e0182852. doi: 10.1371/journal.pone.0182852. eCollection 2017. PLoS One. 2017. PMID: 28800359 Free PMC article.
Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.
Taromi S, Lewens F, Arsenic R, Sedding D, Sänger J, Kunze A, Möbs M, Benecke J, Freitag H, Christen F, Kaemmerer D, Lupp A, Heilmann M, Lammert H, Schneider CP, Richter K, Hummel M, Siegmund B, Burger M, Briest F, Grabowski P. Taromi S, et al. Among authors: freitag h. Oncotarget. 2017 Sep 23;8(57):97061-97078. doi: 10.18632/oncotarget.21221. eCollection 2017 Nov 14. Oncotarget. 2017. PMID: 29228593 Free PMC article.
Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells.
von Hessert-Vaudoncourt C, Lelek S, Geisler C, Hartung T, Bröker V, Briest F, Mochmann L, Jost-Brinkmann F, Sedding D, Benecke J, Freitag H, Wolfshöfer S, Lammert H, Nölting S, Hummel M, Schrader J, Grabowski P. von Hessert-Vaudoncourt C, et al. Among authors: freitag h. Front Pharmacol. 2024 Feb 5;15:1308686. doi: 10.3389/fphar.2024.1308686. eCollection 2024. Front Pharmacol. 2024. PMID: 38375032 Free PMC article.
117 results